Skip to main content

Biosafety evaluation of probiotic lactic acid bacteria used for human consumption

Objective

Probiotic bacteria, mainly lactic acid bacteria (LAB) (e.g. lactobacilli, iactococci, enterococci, and bifidobacteria) have been considered safe for human consumption. However, recent reports of clinical infection, the spread of antibiotic resistance genes, and development of new and/or modified probiotic LAB strains, have caused concern of safety. This project aims to assess the biosafe of LAB. Isolates from healthy humans and immunocompromised patients, commercially available and new probiotic LAB will be studied.

After polyphasic taxonomic identification, their biosafety will be assessed by:
(i) the detection of antibiotic resistance and horizontal transfer of antibiotic resistance genes;
(ii) the detection of known and new virulence properties;
(iii) evaluation of immunological adverse effects of LAB; and
(iv) the survival, colonisation, and genetic stability of probiotic LAB in the human gut.

The project will result in recommendations for biosafe and biosafety testing of LAB, which will be presented and discussed at a final conference.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UNIVERSITAIRE INSTELLING ANTWERPEN - UNIVERSITEIT ANTWERPEN
Address
Universiteitsplein 1 S3
2610 Wilrijk (Antwerpen)
Belgium

Participants (6)

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Switzerland
Address
46,Rue Du Bugnon 46
1011 Lausanne
GENT UNIVERSITY
Belgium
Address
35,K.l. Ledeganckstraat 35
9000 Gent
LEIDEN UNIVERSITY
Netherlands
Address
Albinusdreef 2
2300 RC Leiden
NUMICO RESEARCH B.V.
Netherlands
Address
Bosrandweg 20
6700 CA Wageningen
ROBERT KOCH-INSTITUT
Germany
Address
Nordufer 20
13353 Berlin
UNIVERSITÉ DE LILLE II
France
Address
Rue Du Professeur Laguesse 3
59006 Lille